Literature DB >> 20943876

Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.

Geoffrey J Gorse1, Gira B Patel, Joseph N Vitale, Theresa Z O'Connor.   

Abstract

Little is known about the prevalence of mucosal antibodies induced by infection with human coronaviruses (HCoV), including HCoV-229E and -OC43 and recently described strains (HCoV-NL63 and -HKU1). By enzyme-linked immunosorbent assay, we measured anti-HCoV IgG antibodies in serum and IgA antibodies in nasal wash specimens collected at seven U.S. sites from 105 adults aged 50 years and older (mean age, 67 ± 9 years) with chronic obstructive pulmonary disease. Most patients (95 [90%]) had at least one more chronic disease. More patients had serum antibody to each HCoV strain (104 [99%] had antibody to HCoV-229E, 105 [100%] had antibody to HCoV-OC43, 103 [98%] had antibody to HCoV-NL63, and 96 [91%] had antibody to HCoV-HKU1) than had antibody to each HCoV strain in nasal wash specimens (12 [11%] had antibody to HCoV-229E, 22 [22%] had antibody to HCoV-OC43, 8 [8%] had antibody to HCoV-NL63, and 31 [31%] had antibody to HCoV-HKU1), respectively (P < 0.0001). The proportions of subjects with IgA antibodies in nasal wash specimens and the geometric mean IgA antibody titers were statistically higher for HCoV-OC43 and -HKU1 than for HCoV-229E and -NL63. A higher proportion of patients with heart disease than not had IgA antibodies to HCoV-NL63 (6 [16%] versus 2 [3%]; P = 0.014). Correlations were highest for serum antibody titers between group I strains (HCoV-229E and -NL63 [r = 0.443; P < 0.0001]) and between group II strains (HCoV-OC43 and -HKU1 [r = 0.603; P < 0.0001]) and not statistically significant between HCoV-NL63 and -OC43 and between HCoV-NL63 and -HKU1. Patients likely had experienced infections with more than one HCoV strain, and IgG antibodies to these HCoV strains in serum were more likely to be detected than IgA antibodies to these HCoV strains in nasal wash specimens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943876      PMCID: PMC3008199          DOI: 10.1128/CVI.00278-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  45 in total

1.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.

Authors:  K A Callow
Journal:  J Hyg (Lond)       Date:  1985-08

2.  The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection.

Authors:  A S Monto; S K Lim
Journal:  J Infect Dis       Date:  1974-03       Impact factor: 5.226

3.  Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.

Authors:  G J Gorse; E E Otto; D C Powers; G W Chambers; C S Eickhoff; F K Newman
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

4.  The time course of the immune response to experimental coronavirus infection of man.

Authors:  K A Callow; H F Parry; M Sergeant; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1990-10       Impact factor: 2.451

5.  Role of infection in chronic bronchitis.

Authors:  D W Gump; C A Phillips; B R Forsyth; K McIntosh; K R Lamborn; W H Stouch
Journal:  Am Rev Respir Dis       Date:  1976-04

6.  A previously undescribed coronavirus associated with respiratory disease in humans.

Authors:  Ron A M Fouchier; Nico G Hartwig; Theo M Bestebroer; Berend Niemeyer; Jan C de Jong; James H Simon; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

7.  Effects of coronavirus infections in children.

Authors:  Nicola Principi; Samantha Bosis; Susanna Esposito
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

8.  Antibodies to human coronaviruses 229E and OC43 in the population of C.R.

Authors:  J Hrusková; F Heinz; E Svandová; S Pennigerová
Journal:  Acta Virol       Date:  1990-08       Impact factor: 1.162

9.  Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells.

Authors:  D C Redfield; D D Richman; M N Oxman; L H Kronenberg
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

10.  Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975-1979.

Authors:  O W Schmidt; I D Allan; M K Cooney; H M Foy; J P Fox
Journal:  Am J Epidemiol       Date:  1986-05       Impact factor: 4.897

View more
  72 in total

Review 1.  Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.

Authors:  Nicole Baumgarth; Janko Nikolich-Žugich; F Eun-Hyung Lee; Deepta Bhattacharya
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

Review 2.  Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

3.  The role of antibody tests for COVID-19 in primary care.

Authors:  Azmaeen Zarif; Dylan McGagh; Uy Hoang; Simon de Lusignan
Journal:  Br J Gen Pract       Date:  2021-02-25       Impact factor: 5.386

4.  SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS.

Authors:  Marie-Luise Buchholtz; Florian M Arend; Peter Eichhorn; Michael Weigand; Alisa Kleinhempel; Kurt Häusler; Mathias Bruegel; Lesca M Holdt; Daniel Teupser
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

Review 5.  Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.

Authors:  Pureum Lee; Chang-Ung Kim; Sang Hawn Seo; Doo-Jin Kim
Journal:  Immune Netw       Date:  2021-02-26       Impact factor: 6.303

6.  Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?

Authors:  David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 7.  The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).

Authors:  Narasimha M Beeraka; SubbaRao V Tulimilli; Medha Karnik; Surya P Sadhu; Rajeswara Rao Pragada; Gjumrakch Aliev; SubbaRao V Madhunapantula
Journal:  Biomed Res Int       Date:  2021-06-01       Impact factor: 3.411

8.  Will SARS-CoV-2 Become Just Another Seasonal Coronavirus?

Authors:  Alexander B Beams; Rebecca Bateman; Frederick R Adler
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

9.  Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay.

Authors:  Wegene Borena; Janine Kimpel; Melanie Gierer; Annika Rössler; Lydia Riepler; Susanne Oehler; Dorothee von Laer; Markus Miholits
Journal:  Vaccines (Basel)       Date:  2021-06-07

10.  Seroprevalence of human coronaviruses among patients visiting hospital-based sentinel sites in Uganda.

Authors:  Elijah Nicholas Mulabbi; Robert Tweyongyere; Fred Wabwire-Mangen; Edison Mworozi; Jeff Koehlerb; Hannah Kibuuka; Monica Millard; Bernard Erima; Titus Tugume; Ukuli Qouilazoni Aquino; Denis K Byarugaba
Journal:  BMC Infect Dis       Date:  2021-06-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.